JP2018535681A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535681A5 JP2018535681A5 JP2018526797A JP2018526797A JP2018535681A5 JP 2018535681 A5 JP2018535681 A5 JP 2018535681A5 JP 2018526797 A JP2018526797 A JP 2018526797A JP 2018526797 A JP2018526797 A JP 2018526797A JP 2018535681 A5 JP2018535681 A5 JP 2018535681A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- bond
- fibrosis
- colitis
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 46
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 43
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 36
- 208000027866 inflammatory disease Diseases 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 26
- 206010009887 colitis Diseases 0.000 claims description 24
- 206010016654 Fibrosis Diseases 0.000 claims description 18
- 230000004761 fibrosis Effects 0.000 claims description 18
- 206010009944 Colon cancer Diseases 0.000 claims description 16
- 208000011231 Crohn disease Diseases 0.000 claims description 16
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 14
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 208000009326 ileitis Diseases 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 201000001245 periodontitis Diseases 0.000 claims description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 206010072877 Intestinal fibrosis Diseases 0.000 claims description 5
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000009137 Behcet syndrome Diseases 0.000 claims description 4
- 206010009895 Colitis ischaemic Diseases 0.000 claims description 4
- 206010056979 Colitis microscopic Diseases 0.000 claims description 4
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 4
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 206010036774 Proctitis Diseases 0.000 claims description 4
- 206010036783 Proctitis ulcerative Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 4
- 208000036379 Sigmoiditis Diseases 0.000 claims description 4
- 230000009787 cardiac fibrosis Effects 0.000 claims description 4
- 208000008609 collagenous colitis Diseases 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000010227 enterocolitis Diseases 0.000 claims description 4
- 208000027792 gastroduodenal Crohn disease Diseases 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 201000008254 ileocolitis Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 201000008222 ischemic colitis Diseases 0.000 claims description 4
- 208000004341 lymphocytic colitis Diseases 0.000 claims description 4
- 208000008275 microscopic colitis Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 239000000049 pigment Substances 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 4
- 201000002793 renal fibrosis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000009890 sinusitis Diseases 0.000 claims description 4
- 206010040882 skin lesion Diseases 0.000 claims description 4
- 231100000444 skin lesion Toxicity 0.000 claims description 4
- 201000004595 synovitis Diseases 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 230000016396 cytokine production Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000028709 inflammatory response Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 206010028537 myelofibrosis Diseases 0.000 claims description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078549A JP2021106625A (ja) | 2015-11-25 | 2021-05-06 | Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260076P | 2015-11-25 | 2015-11-25 | |
| US62/260,076 | 2015-11-25 | ||
| PCT/EP2016/078833 WO2017089555A1 (en) | 2015-11-25 | 2016-11-25 | Il-34 antisense oligonucleotides and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078549A Division JP2021106625A (ja) | 2015-11-25 | 2021-05-06 | Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018535681A JP2018535681A (ja) | 2018-12-06 |
| JP2018535681A5 true JP2018535681A5 (https=) | 2020-01-09 |
Family
ID=57471829
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526797A Pending JP2018535681A (ja) | 2015-11-25 | 2016-11-25 | Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法 |
| JP2021078549A Pending JP2021106625A (ja) | 2015-11-25 | 2021-05-06 | Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078549A Pending JP2021106625A (ja) | 2015-11-25 | 2021-05-06 | Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180338992A1 (https=) |
| EP (1) | EP3380615B1 (https=) |
| JP (2) | JP2018535681A (https=) |
| KR (1) | KR20180084956A (https=) |
| CN (1) | CN108473989A (https=) |
| AU (1) | AU2016360956A1 (https=) |
| BR (1) | BR112018010736A2 (https=) |
| CA (1) | CA3005932A1 (https=) |
| ES (1) | ES2861516T3 (https=) |
| MA (1) | MA44309A (https=) |
| MX (1) | MX2018006445A (https=) |
| PT (1) | PT3380615T (https=) |
| WO (1) | WO2017089555A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019505598A (ja) * | 2016-02-23 | 2019-02-28 | セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー | Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法 |
| CN114729363A (zh) * | 2019-11-15 | 2022-07-08 | 诺格拉制药有限公司 | Il-34反义剂及其使用方法 |
| AU2022276078A1 (en) | 2021-05-17 | 2024-01-04 | Nogra Pharma Limited | Il-34 antisense agents and methods of using same |
| WO2022243299A1 (en) * | 2021-05-17 | 2022-11-24 | Nogra Pharma Limited | Il-34 antisense agents and methods of using same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| WO2009090639A2 (en) * | 2008-01-15 | 2009-07-23 | Quark Pharmaceuticals, Inc. | Sirna compounds and methods of use thereof |
| ES2627745T3 (es) | 2008-11-13 | 2017-07-31 | Nogra Pharma Limited | Composiciones antisentido, y procedimientos de fabricación y uso de las mismas |
| GB0910833D0 (en) * | 2009-06-23 | 2009-08-05 | Univ Edinburgh | Avian genes |
| WO2011097407A1 (en) * | 2010-02-04 | 2011-08-11 | Ico Therapeutics Inc. | Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
| AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| JP2014520873A (ja) * | 2011-07-18 | 2014-08-25 | ザ ユニバーシティ オブ メルボルン | ｃ−Ｆｍｓアンタゴニストの使用 |
| CN107759690A (zh) * | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| GB201315486D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| KR20150104275A (ko) * | 2014-03-05 | 2015-09-15 | 울산대학교 산학협력단 | 비만 관련 질환의 진단과 치료를 위한 il-34의 용도 |
| ES3047792T3 (en) * | 2014-07-14 | 2025-12-04 | Univ California | Crispr/cas transcriptional modulation |
-
2016
- 2016-11-25 PT PT168053510T patent/PT3380615T/pt unknown
- 2016-11-25 US US15/778,688 patent/US20180338992A1/en not_active Abandoned
- 2016-11-25 CN CN201680077787.9A patent/CN108473989A/zh active Pending
- 2016-11-25 MX MX2018006445A patent/MX2018006445A/es unknown
- 2016-11-25 MA MA044309A patent/MA44309A/fr unknown
- 2016-11-25 CA CA3005932A patent/CA3005932A1/en not_active Abandoned
- 2016-11-25 EP EP16805351.0A patent/EP3380615B1/en active Active
- 2016-11-25 AU AU2016360956A patent/AU2016360956A1/en not_active Abandoned
- 2016-11-25 JP JP2018526797A patent/JP2018535681A/ja active Pending
- 2016-11-25 BR BR112018010736A patent/BR112018010736A2/pt not_active IP Right Cessation
- 2016-11-25 KR KR1020187017448A patent/KR20180084956A/ko not_active Withdrawn
- 2016-11-25 ES ES16805351T patent/ES2861516T3/es active Active
- 2016-11-25 WO PCT/EP2016/078833 patent/WO2017089555A1/en not_active Ceased
-
2021
- 2021-05-06 JP JP2021078549A patent/JP2021106625A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535681A5 (https=) | ||
| JP2018199700A5 (https=) | ||
| Oikawa | ETS transcription factors: possible targets for cancer therapy | |
| AU2017224226A1 (en) | Compositions and methods of using piRNAs in cancer diagnostics and therapeutics | |
| JP2019522461A5 (https=) | ||
| JP2019503167A5 (https=) | ||
| JP2012508560A5 (https=) | ||
| TW201803989A (zh) | 拮抗ｂ型肝炎病毒之組成物和藥劑及彼等之用途 | |
| JP2011526482A5 (https=) | ||
| JP2017532982A (ja) | Ｓｍａｄ７アンチセンスオリゴヌクレオチドの同位体置換体 | |
| JP2012528572A5 (https=) | ||
| JP2014518612A5 (https=) | ||
| JP2011515078A5 (https=) | ||
| CN105308182A (zh) | 修饰的TGF-β2寡核苷酸 | |
| JP2016538885A5 (https=) | ||
| JP2007505627A5 (https=) | ||
| JP2016502858A5 (https=) | ||
| JP2017532982A5 (https=) | ||
| IL277970B2 (en) | Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease | |
| JPWO2019156137A5 (https=) | ||
| JP2017529321A5 (https=) | ||
| JP2021511072A5 (https=) | ||
| IL309411A (en) | RNA treatments and their uses | |
| JP6450718B2 (ja) | 交替式捕捉トランスレータ | |
| IL275902B2 (en) | Antisense oligonucleotides directed against alpha-synuclein and their uses |